Arca Biopharma | ABIO - Cash And Equivalent


Arca Biopharma reported $91.25M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Amgen USD 9.13B 316M Dec/2025
Arca Biopharma USD 91.25M 25.86M Sep/2025
Biogen USD 3.01B 854.3M Dec/2025
Brainstorm Cell Therapeutics USD 5K 819K Sep/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Capricor Therapeutics USD 19.51M 3.73M Sep/2025
Cipla INR 7.96B 39.9M Sep/2025
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 7.46M 985K Sep/2025
CSL USD 2.16B 633M Jun/2025
Cytokinetics USD 122.52M 102.95M Dec/2025
Daiichi Sankyo JPY 542.16B 97.68B Sep/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Grifols EUR 979.78M 334.84M Dec/2024
Laboratory Of America USD 532.3M 65.8M Dec/2025
Myriad Genetics USD 145.4M 71M Sep/2025
Otsuka Holdings JPY 411.11B 3.62B Jun/2025
Pfizer USD 1.34B 295M Sep/2025
United Therapeutics USD 1.56B 217M Dec/2025